Sie sind auf Seite 1von 7

Global Cardiac Bio

Marker Diagnostic
Test Market
Share, Global Trends,
Analysis, Research, Report,
Segmentation and Forecast,

Future Market Insights

Report Description
Cardiac Bio-Marker Diagnostic Test market includes the diagnostic tests used to measure
the concentration of proteins, also known as biomarkers that indicate the occurrence and
phase of cardiovascular disease (CVD). Cardiac biomarkers evaluate the heart function
and aid in identifying the complexity and severity of procedures further required to treat
the cardiovascular disease. The primary indications for cardiovascular diseases are Acute
Coronary Syndrome (ACS) which include Angina Pectoris (AP) and Acute Myocardial
Infraction (AMI) Congestive Heart Failure (CHF), Peripheral Artery Disease (PAD) and
others. The major causes of CVD are High Blood Pressure, smoking, diabetes, inadequate
exercise, stress, unhealthy diet, alcoholism, obesity and high blood cholesterol. More
than half of the cardiovascular diseases can be cured if diagnosed at the right time.
Cardiovascular diseases are one of the leading causes of deaths globally with around 35%
cardiovascular related deaths worldwide in 2013. As per WHO, 17.5 million people died
from CVDs in 2012, representing 31% of all global deaths. Of these deaths, an estimated
7.4 million were due to coronary heart disease or ACS which represent around 42% of
the cardiovascular deaths.
Browse Full Report@
It is also estimated that each year approximately around 17 million people die of
cardiovascular disease due to inappropriate diagnosis and it represents untapped market
opportunity for cardiac biomarker diagnostic test market.
Cardiac Bio-Marker Diagnostic Test Market: Drivers & Restraints

Report Description
In-Vitro Diagnostics is the parent market for cardiac biomarker diagnostic test. In-vitro
diagnostic refers to tests done using body samples of blood, urine, biopsies or tissue
sections outside the body.

The increasing incidences of CVD is major driver for cardiac biomarkers market. Cardiac
biomarkers are used in hospitals either to diagnose cardiac injury in an emergency or to
evaluate the future risk of cardiovascular disease. The use of cardiac biomarker
diagnostic tests will reduce the expenditure of patients on hospitals. Increase adoption of
new diagnostic tools among healthcare professionals and affordability for patients are
some of the few factors driving the growth of this market.
With continuous development of the market, few tests reaching its saturation will always
remain a key restrains for this market.
Cardiac Bio-Marker Diagnostic Test Market: Segmentation
Cardiac Bio-Marker tests are broadly classified based on indications and usage:

Troponin Tests
Creatine Kinase MB (CK-MB) Tests
B-type Natriuretic Peptide (BNP) Tests
D-Dimer Tests

Others Tests

Report Description
Cardiac Bio-Marker Diagnostic Test Market: Overview
With rapid acceptance of these tests worldwide by healthcare professionals, Cardiac BioMarkers diagnostic test have huge potential and is expected to grow at a higher rate in
the forecast period (2016-2025). Effective implementation of these bio-markers have
enabled healthcare institutions with decreased bed occupancy, reduction in the hospital
cost and physician time.
Cardiac Bio-Marker Diagnostic Test Market: Regional Outlook
The number of deaths due to cardiovascular diseases are increasing in developing
nations, while the number has decreased in the developed nations. Europe is a lucrative
market for cardiac biomarker diagnostic test due to the initiatives of constant heart
health monitoring through cardiac biomarker diagnostic test to reduce this high death
Request Report TOC@

The global cardiac bio-marker diagnostic test market is expected to register a significant
growth for the forecast period. Depending on geographic regions, global cardiac biomarker diagnostic test devices market is segmented into seven key regions: North
America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle
East & Africa. As of 2015, North America, and Western Europe dominated global cardiac
bio-marker diagnostic test market in terms of market revenue. Asia-Pacific & Japan is
projected to grow at a substantial growth and will contribute to the global cardiac bio-

Report Description
Cardiac Bio-Marker Diagnostic Test Market: Key Players
The key players in cardiac biomarker diagnostic test market are Abbott Laboratories,
Beckman Coulter, Roche Diagnostics, Bio-Rad Laboratories Inc., Siemens Healthcare
Diagnostics, Cardiogenics Inc., and Life Sign LLC. The cardiac biomarker diagnostic test
market players can develop prospects in customised cardiac biomarker diagnostic test
solutions. They can opt for improving the cardiac biomarker diagnostic test efficiency by
including multiple options in it. The cardiac biomarker diagnostic test market players can
form associations with pharmaceutical companies to deliver better performing cardiac
biomarker diagnostic tests that meet patient needs appropriately.

About Us

Future Market Insights (FMI) is a premier provider of syndicated
research reports, custom research reports, and consulting services.
We deliver a complete packaged solution, which combines current
market intelligence, statistical anecdotes, technology inputs,
valuable growth insights, aerial view of the competitive
framework, and future market trends.
We provide research services at a global as well as regional level;
key regions include GCC, ASEAN, and BRIC.
Research Capabilities

Customized Research
Syndicated Research
Investment Research
Social Media Research

Sector Coverage

Automotive and Transportation

Electronics, Semiconductor, and ICT
Retail and Consumer Products
Industrial Automation and Equipment
Chemicals & Materials
Food and Beverages
Services and Utilities
Energy, Mining, Oil, and Gas

Thank You!

To know more about us, please visit our website:
For sales queries or new topics email us on:
For other queries contact: Mr. Sudip Saha
Future Market Insights: 616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
T: +1-347-918-3531 | D: +1-845-579-5705